The Lateral flow assay market in the Middle East and Africa was valued at USD 554.37 Million in 2022. It is expected to reach USD 763.43 Million by 2027, growing at 6.609% CAGR from 2022 to 2027.
Lateral flow assays are widely used in hospitals and clinical laboratories for the qualitative and quantitative detection of specific antigens and antibodies, which helps diagnose infectious disease, cardiac markers, pregnancy, fertility testing, lipid profile testing, drug abuse, etc. Lateral flow assay kits are convenient, smaller, portable, and controlled with minimal training; hence these tests are becoming more popular over other testing kits. They act as a one-step test that does not require any washing, refrigeration, or pretreatment steps. They are also faster testing procedures that provide qualitative or semi-quantitative results, need relatively short development time, and allow batch preparation in advance.
The growth of the MEA lateral flow testing market is mainly driven by factors such as the increase in the use of home lateral flow assay testing kits, favorable government initiatives, increasing demand for food and drinks testing, growing healthcare awareness, increased adoption of assays due to innovations and rapid technological development for rapid laboratory testing. In addition, communicable infectious diseases such as HIV require new diagnostic methods of effective treatment to stop the increasing death rate. For example, according to the Joint United Nations Program on HIV and AIDS-2019, nearly 25 million people have HIV undergoing antiretroviral therapy across the globe.
Various players in the emerging market have seen a great demand for advanced healthcare needs, and advanced technology products will create many opportunities for the market in the MEA region. This, along with the lack of extensive laboratory facilities or skilled healthcare workers to efficiently perform other laboratory tests, drives the market growth. In addition, key players are introducing new signal enhancement techniques and improving simultaneous detection and quantization systems, thereby creating favorable market prospects.
On the other hand, some regions in MEA still prefer the existing diagnostic tests over lateral flow assay, and lack of healthcare development, especially in developing economies, are some of the factors that will challenge this market's growth.
This research report on the Middle East and Africa lateral flow assay market has been segmented and sub-segmented into the following categories:
By End User:
In 2020, the Middle East region accounted for the majority of the MEA lateral flow assays market, and this trend is expected to continue until the end of the projected period. During 2020-2022, the regional MEA markets showed great revenue collection due to increased infectious disease by the COVID-19 virus. This had raised the number of hospitals and clinics adopting the tests to detect the virus. As of 2022, Iran had the highest number of confirmed coronavirus cases in the MEA region, with more than three million cases. According to the World Health Organization, World Tuberculosis Report 2020, around 1.5 million deaths were reported due to tuberculosis-related complications in 2019, and nearly 11 million people contracted tuberculosis in 2019. As a result, the growing burden of tuberculosis is expected to drive the need for affordable diagnostics, especially in developing countries, helping the studied market grow.
Saudi Arabia and the United Arab Emirates are relatively mature markets for lateral flow assay. At the same time, regions in Africa will show lower growth rates owing to underdeveloped economies in the region. Factors such as increased awareness, a large geriatric population, and a growing healthcare infrastructure market are driving the growth of this market in these regions.
KEY MARKET PLAYERS:
Companies playing a prominent role in the MEA lateral flow assay market profiled in the report are Alere Inc., F. Hoffmann-La Roche AG, Danaher Corporation, Siemens AG, Becton, Dickinson and Company, bioMérieux SA, Johnson & Johnson, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., and PerkinElmer Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org